Abstract
Objectives: The main objective of the present study was to investigate the prevalence and type of medication taken by MCI patients in the DECRIPA cohort. A secondary objective was to assess the cognitive function of these patients and the relationship between the results of neuropsychometric tests and medication use.
Materials and Methods: We selected 880 subjects (375 males, 505 females) who were older than 55 years without obvious causes of cognitive impairment. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken. Comparisons between groups were statistically analyzed in relation to the number of medications.
Results: Most patients (85.7%, n=754) were taking at least one medication during the study period. The median (interquartile range-IQ) number of medications per participant was 3 (1–5), whereas 40% of the patients took at least 4 medications. The types of medications that were most often taken were cardiovascular drugs (62.0%), antidepressants (16.8%), sedatives (14.6%), thyroid drugs (10.0%) and anti-diabetic drugs (7.6%).
Conclusion: On average, MCI patients take three medications for the prevention or treatment of an average of two medical conditions. The most prevalent types of medications were cardiovascular drugs, antidepressants, sedatives and thyroid drugs. Significant differences in the number of medications taken were observed for gender and age.
Keywords: Alzheimer's disease, anticholinergic drugs. co-morbidity, medication, mild cognitive impairment.
Current Alzheimer Research
Title:MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study
Volume: 13 Issue: 12
Author(s): Magda Tsolaki, Vasileios Papaliagkas, Giovanni Frisoni, Roy Jones, Jacques Touchon, Luiza Spiru, Bruno Vellas, Frans Verhey, Bengt Winblad, Pieter Jelle Visser and on behalf of the DESCRIPA Study Group
Affiliation:
Keywords: Alzheimer's disease, anticholinergic drugs. co-morbidity, medication, mild cognitive impairment.
Abstract: Objectives: The main objective of the present study was to investigate the prevalence and type of medication taken by MCI patients in the DECRIPA cohort. A secondary objective was to assess the cognitive function of these patients and the relationship between the results of neuropsychometric tests and medication use.
Materials and Methods: We selected 880 subjects (375 males, 505 females) who were older than 55 years without obvious causes of cognitive impairment. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken. Comparisons between groups were statistically analyzed in relation to the number of medications.
Results: Most patients (85.7%, n=754) were taking at least one medication during the study period. The median (interquartile range-IQ) number of medications per participant was 3 (1–5), whereas 40% of the patients took at least 4 medications. The types of medications that were most often taken were cardiovascular drugs (62.0%), antidepressants (16.8%), sedatives (14.6%), thyroid drugs (10.0%) and anti-diabetic drugs (7.6%).
Conclusion: On average, MCI patients take three medications for the prevention or treatment of an average of two medical conditions. The most prevalent types of medications were cardiovascular drugs, antidepressants, sedatives and thyroid drugs. Significant differences in the number of medications taken were observed for gender and age.
Export Options
About this article
Cite this article as:
Tsolaki Magda, Papaliagkas Vasileios, Frisoni Giovanni, Jones Roy, Touchon Jacques, Spiru Luiza, Vellas Bruno, Verhey Frans, Winblad Bengt, Visser Jelle Pieter and on behalf of the DESCRIPA Study Group , MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160603002704
DOI https://dx.doi.org/10.2174/1567205013666160603002704 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews Chronic Kidney Disease and Sleeping Disordered Breathing (SDB)
Current Hypertension Reviews Potential Inhibitors of Protein Tyrosine Phosphatase (PTP1B) Enzyme: Promising Target for Type-II Diabetes Mellitus
Current Topics in Medicinal Chemistry Diabetes, Sexual Dysfunction and Therapeutic Exercise: A 20 Year Review
Current Diabetes Reviews PPAR Ligands Containing Stilbene Scaffold
Mini-Reviews in Medicinal Chemistry Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry AMPK Activators as Novel Therapeutics for Type 2 Diabetes
Current Topics in Medicinal Chemistry Putative Involvement of Endocrine Disruptors in the Alzheimer's Disease Via the Insulin-Regulated Aminopeptidase/GLUT4 Pathway
Current Neuropharmacology Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Effect of Vitamin D<sub>3</sub> on Lifespan in Caenorhabditis elegans
Current Aging Science Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design Role of Ischemia Modified Albumin Serum Levels as an Oxidative Stress Marker in Children with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
Current Vascular Pharmacology Insights into the Role of DNA Methylation and Protein Misfolding in Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Current Pharmaceutical Design Pregnancy and Viral Hepatitis: Current Concepts
Current Pharmaceutical Design The Pyruvate Dehydrogenase Complex as a Target for Gene Therapy
Current Gene Therapy